Janssen-Cilag International NV Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adu

VIENNA--(BUSINESS WIRE)--

Poster to be presented on Thursday 18th September 2014 13:00-14:00 (Vienna Time)

Note: This press release corresponds to EASD abstract #855

Janssen-Cilag International NV (Janssen) today announced results from four 26-week placebo-controlled studies and pooled data from two 52-week active controlled trials, showing that INVOKANA® (canagliflozin) relative to placebo was efficacious across the spectrum of insulin sensitivity and beta cell function in lowering blood glucose.1 These results are among 10 abstracts for canagliflozin being presented at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria (abstract #855).

Help employers find you! Check out all the jobs and post your resume.